Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2Phase NA 1Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 1Paraganglioma, Extra-Adrenal 1Carcinoma, Medullary 1

Interventions

lenvatinib 1fluorodopa F 18 1cabozantinib 1Thyroidectomy 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Restraint, Physical 1Radiofrequency Ablation 1Practice Guidelines as Topic 1Neck Dissection 1Magnetic Resonance Spectroscopy 1Laser Therapy 1High-Energy Shock Waves 1Gefitinib 1Ferrosoferric Oxide 1Decision Support Techniques 1Cryosurgery 1Cryoelectron Microscopy 1Absorptiometry, Photon 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Carcinoma, Medullary × cabozantinib × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡